
Bristol-Myers Squibb has pulled back the veil on new data from two analyses of its blockbuster immunotherapy Opdivo (nivolumab) in …

MRI scans can predict MS patient’s long term prognosis when they are first diagnosed, according to new research. In a …

Researchers at Purdue University are developing a device that would automatically detect an overdose in opioid users and release a …

Eli Lilly has been awarded approval from the FDA for its Baqsimi nasal powder in the treatment of severe hypoglycaemia, …

Elizabeth Warren has called on Pfizer to reveal the details of Scott Gottlieb’s appointment to the company’s Board of Directors.

Business chief Jonathan Symonds has joined British multinational GlaxoSmithKline as the company’s new non-executive chairman. The hire ends GSK’s six …

Chief Executive Mike Thompson is to retire from his role at the Association of the British Pharmaceutical Industry (ABPI) by …

It’s another victory for MSD as the US drugmaker announced that its biosimilar version of AbbVie’s Humira – the world’s …

The Senate Finance Committee has introduced a bipartisan bill that aimed at lowering the prices Medicare pays for pharmaceutical drugs. …

Pfizer has seen Ruxience, its biosimilar version of Genentech’s Rituxan (rituximab), approved by the FDA in the treatment of non-Hodgkin …

Anonymised data can be traced back to individuals, according to research published in the journal Nature Communications. Anonymised data can …

MSD is trialling an implant that prevents patients from contracting HIV, The Guardian has said. The US firm has tested …

Massachusetts-based biotech Disarm Therapeutics has hired Dr Alvin Shih as their new President and CEO. The Cambridge, Mass.-based firm has …

Takeda has unveiled new Phase 3 data for a subcutaneous formulation of its gut-selective biologic Entyvio (vedolizumab), showing that the …

Drug resistant malaria parasites are spreading rapidly in South East Asia, according to researchers from Thailand and the United Kingdom. …

The FDA has given its approval to the first generic versions of Pfizer’s Lyrica (pregabalin), it has emerged, giving the …

Acadia Pharmaceuticals has said its schizophrenia drug Nuplazid (primavanserin) has failed to beat placebo in a Phase 3 trial. Nuplazid …

Gilead has acquired the rights to three of Novartis’ preclinical antiviral programmes, including investigational compounds with the potential to treat …

Biohaven Pharmaceutical has seen its new therapy formulation for the treatment of amyotrophic lateral sclerosis (ALS) rejected by the FDA, …

Britain’s cost-effectiveness body NICE has said it will review the methods it uses to develop guidance on drugs, medical devices, …